Biblio
Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome. Stem Cell Res. 2021;54:102402.
. Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations. Stem Cell Res. 2021;55:102455.
. Generation of three induced pluripotent stem cell lines, SCVIi003-A, SCVIi004-A, SCVIi005-A, from patients with ARVD/C caused by heterozygous mutations in the PKP2 gene. Stem Cell Res. 2021;53:102284.
. Generation of three induced pluripotent stem cell lines (SCVIi014-A, SCVIi015-A, and SCVIi016-A) from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene. Stem Cell Res. 2021;55:102492.
. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy. Stem Cell Res. 2021;53:102279.
. Generation of two induced pluripotent stem cell lines from patients suffering from pulmonary hypertension. Stem Cell Res. 2023;72:103218.
. Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants. Stem Cell Res. 2022;61:102774.
. SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common alcohol flushing variant. Sci Transl Med. 2023;15(680):eabp9952.